AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03108196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sigmoid
Description: The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
Study NCT02449954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine sulphate
Description: Group I:received IV 0.1mg/kg morphine sulphate.
Study NCT02449954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tramadol HCL
Description: Group II:received IV 2 mg/kg tramadol HCL.
Study NCT02449954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketorolac tromethamine
Description: Group III: received IV 30 mg ketorolac tromethamine
Study NCT02917551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of adequate antibiotic treatment
Study NCT02917551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of adequate antibiotic treatment
Study NCT03904641 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
Study NCT03904641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART
Description: Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
Study NCT03108196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ileal
Description: The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
Study NCT03352765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
Study NCT03352765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: bendamustine 160 mg/m2 intravenously on days -3 and -2
Study NCT03352765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
Study NCT03352765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation (ASCT)
Description: reinfusion of autologous stem cells on day 0.
Study NCT03038672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03038672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04727502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: duloxetine
Study NCT04727502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregablin
Description: Pregablin
Study NCT03038672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Given IV
Study NCT00317837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar Hemiarthroplasty of the hip joint
Description: Unipolar Hemiarthroplasty of the hip joint
Study NCT00317837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar hemiarthroplasty
Description: bipolar hemiarthroplasty
Study NCT02915497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abbreviated Early Prolonged Exposure Therapy
Description: Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
Study NCT02969577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
Study NCT02969577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Nutrition Coaching
Description: Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
Study NCT02969577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care with Attention
Description: Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
Study NCT02969577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care with Attention
Description: Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
Study NCT03209258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care bundle of active management
Description: 1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets.
Study NCT03209258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
Study NCT03419494 — intervention group
Intervention type: DRUG
Intervention: PLD
Description: PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Study NCT03419494 — intervention group
Intervention type: DRUG
Intervention: DNR
Description: DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
Study NCT00181753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope study
Description: 7 hours of primed constant infusion of stable isotope tracers.
Study NCT05514652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low opioid anesthesia
Description: Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
Study NCT05514652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low opioid anesthesia
Description: Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
Study NCT02614820 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Remote Ischemic Preconditioning Training Apparatus
Study NCT02614820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning Training Apparatus
Study NCT03057704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine injection flushed
Description: The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
Study NCT03057704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injection tourniquet
Description: Intravenous lidocaine: tourniquet
Study NCT01876381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
Study NCT01987557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rate group
Description: walking with a high cadence (steps per minute)
Study NCT01987557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: magnitude treadmill group
Study NCT01987557 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular treadmill walking
Study NCT02373592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS and voice messaging
Description: This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care).
Study NCT02373592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermometry
Description: Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
Study NCT02373592 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Thermometry
Description: Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
Study NCT03400423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.
Study NCT03400423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
Study NCT04293198 — intervention group
Intervention type: DEVICE
Intervention: KODEX-EPD System
Description: The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
Study NCT04293198 — intervention group
Intervention type: DEVICE
Intervention: Fluoroscopy with contrast dye
Description: Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
Study NCT04250701 — intervention group
Intervention type: OTHER
Intervention: Body Posture Assessment
Description: Application of three evaluations above at a one time.
Study NCT02659085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV Infusion
Description: Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
Study NCT02659085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
Study NCT02051192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Led Exposure Therapy
Description: Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
Study NCT02051192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
Study NCT02723604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
Study NCT00775502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIW-8962
Description: Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
Study NCT03961126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of autologous fatty tissue associated with autologous platelet-rich plasma.
Description: Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
Study NCT03961126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (clobetasol 0.05%)
Description: Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
Study NCT01918189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral pain self-management intervention Pain EASE
Description: 10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
Study NCT03868358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks
Study NCT03868358 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks
Study NCT05631444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-based therapy
Description: One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
Study NCT01608724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: oral, 5 mg once a day (Q.D.)
Study NCT02457182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Study NCT02457182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical therapy
Study NCT02457182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual medical therapy
Study NCT05631444 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cell-based therapy
Description: One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
Study NCT05430061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: slowly digestible carbohydrate
Description: carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
Study NCT05430061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: slowly digestible carbohydrate
Description: carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
Study NCT02216526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil® Restoraderm
Study NCT02216526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excipial
Study NCT04104906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control training
Description: The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
Study NCT04104906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The exercise group
Description: the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
Study NCT02690142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose i.v.
Study NCT02690142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 i.v.
Description: Single dose i.v.
Study NCT02690142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035 s.c.
Description: Single dose s.c.
Study NCT00181753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours of primed constant stable isotope tracer infusion.
Study NCT00529633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide by mouth at night for a total of 24 weeks
Study NCT00529633 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo by mouth at night for a total of 24 weeks
Study NCT03621280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoketoconazole
Description: Levoketoconazole up to 1200 mg daily
Study NCT02553629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Study NCT02553629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT02801786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The arm will be composed of 03 women who used placebo capsules and gel.
Study NCT02801786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The arm will be composed of 03 women who used placebo capsules and gel.
Study NCT02801786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
Study NCT02801786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
Study NCT01337570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months